Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02263105 : Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Histological diagnosis of primary tumor as high-grade gliomas (WHO III or IV)

- All patients should complete radiation therapy for primary gliomas.

- MRI showed unequivocal evidence of tumor recurrence or progression.

- The time to be enrolled should be more than 90 days after the radiation therapy.

- Written informed consent

- Eastern Cooperative Oncology Group(ECOG) score: 0-2

- The patients with recurrent gliomas were treated without dose-dense TMZ therapy before
enrollment.

- Surgical interventions for recurrent gliomas are permitted and patients with no
residual tumor are permitted

Exclusion Criteria:

- Abnormal function of liver or renal (value more than 1.5 fold normal upper limit)

- Blood routing: Hb < 90g/L, absolute neutrophil count?1.5*10^9/L, platelet < 100*10^9/L

- Pregnant or lactating women

- Allergic to administered drugs

- Radiation therapy in the previous 90 days before enrollment

- The patients with recurrent gliomas were treated with dose-dense TMZ therapy before
enrollment.

- Acute infection in need of antibiotics intravenously

- Participation in other clinical trials in the 90 days before enrollment
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02263105      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740